NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 121 filers reported holding NURIX THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,398,040 | -2.6% | 814,000 | +61.5% | 0.59% | -33.9% |
| Q3 2022 | $6,569,000 | -47.9% | 504,144 | -49.3% | 0.89% | -54.6% |
| Q2 2022 | $12,600,000 | -11.1% | 994,492 | -1.7% | 1.97% | +7.5% |
| Q1 2022 | $14,173,000 | -34.1% | 1,011,638 | +36.1% | 1.83% | -15.1% |
| Q4 2021 | $21,517,000 | +172.2% | 743,238 | +181.6% | 2.15% | +74.8% |
| Q3 2021 | $7,906,000 | – | 263,900 | – | 1.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |